Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Vet Comp Oncol ; 16(1): 20-27, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28168776

ABSTRACT

BACKGROUND: Mast cell tumors (MCT) are common splenic tumors in cats, but there is limited information on treatment outcomes of cats with this disease. MATERIALS AND METHODS: This retrospective study evaluated treatment outcomes in 64 cats with splenic MCT. Cats were categorized into the following treatment groups: splenectomy (A, n = 20); splenectomy with chemotherapy (B, n = 20); chemotherapy alone (C, n = 15); or supportive care (D, n = 9). RESULTS: Median tumor specific survival (MTSS) was: 856, 853, 244, 365 days for groups A, B, C, and D, respectively. The MTSS was not significantly different between the 4 groups. However, comparing cats that had splenectomy (A and B) versus those that did not (C and D), the MTSS was 856 and 342 days, respectively (p=0.008). None of the prognostic factors analyzed significantly influenced survival. CONCLUSION: Splenectomy (+/- chemotherapy) significantly prolongs survival in cats with mast cell tumors. The role of chemotherapy remains unknown.


Subject(s)
Cat Diseases/diagnosis , Mastocytosis/veterinary , Splenic Neoplasms/veterinary , Animals , Antineoplastic Agents/therapeutic use , Cat Diseases/drug therapy , Cat Diseases/surgery , Cat Diseases/therapy , Cats , Combined Modality Therapy/veterinary , Female , Male , Mastocytosis/diagnosis , Mastocytosis/drug therapy , Mastocytosis/therapy , Prognosis , Retrospective Studies , Splenectomy/veterinary , Splenic Neoplasms/diagnosis , Treatment Outcome
2.
J Vet Intern Med ; 30(1): 230-41, 2016.
Article in English | MEDLINE | ID: mdl-26687731

ABSTRACT

BACKGROUND: Ovarian hormones play crucial roles in mammary carcinogenesis. However, whether ovarian ablation by ovariohysterectomy (OHE) improves the prognosis in dogs with mammary carcinomas is unclear. OBJECTIVES: Determine if OHE at the time of mastectomy improves the prognosis in dogs with mammary carcinomas and evaluate if hormonal factors influence the effect of OHE. ANIMALS: Sixty intact dogs with mammary carcinomas. METHODS: Dogs were randomly assigned in a 1:1 ratio to undergo OHE (n = 31) or not (n = 29) at the time of tumor removal. Peri-surgical serum estradiol (E2) and progesterone concentrations were measured, tumor diagnosis was confirmed histologically, and tumor estrogen and progesterone receptor status was immunohistochemically determined. The dogs were monitored for recurrence and metastases every 3-4 months for at least 2 years. Uni- and multivariable survival analyses were performed with relapse and all-cause death as endpoints in addition to univariable subgroup analyses. RESULTS: Overall, OHE did not significantly decrease hazard of relapse (hazard ratio [HR], 0.64; P = .18) or all-cause death (HR, 0.87; P = .64) in univariable analyses. In multivariable analysis OHE did not significantly influence the hazard of relapse (HR, 0.54; P = .12), but an interaction effect was identified between ER status and E2 (P = .037). Subgroup analysis identified decreased hazard of relapse in the OHE group compared to the non-OHE group in the subsets of dogs with increased E2 (HR, 0.22; P = .012) or grade 2 tumors (HR, 0.26; P = .02). CONCLUSION: Dogs with grade 2, ER-positive tumors, or with increased peri-surgical serum E2 concentration represent a subset of dogs with mammary carcinomas likely to benefit from OHE.


Subject(s)
Dog Diseases/surgery , Hysterectomy/veterinary , Mammary Neoplasms, Animal/surgery , Ovariectomy/veterinary , Animals , Dogs , Female , Risk Factors , Secondary Prevention
3.
J Vet Intern Med ; 29(3): 900-7, 2015.
Article in English | MEDLINE | ID: mdl-25900646

ABSTRACT

BACKGROUND: Survival times and tumor responses associated with malignant neoplasia of the lower urinary tract are poor despite the vast array of current treatments. Therefore, the evaluation of alternative treatments, such as intraarterial administration of chemotherapy (IAC) should be considered. OBJECTIVE: To describe a technique for superselective catheterization for IAC and to evaluate initial tumor response by ultrasonography after both IAC and intravenous administration of chemotherapy (IVC). ANIMALS: Client-owned dogs with lower urinary tract neoplasia treated with either IVC (n = 15) or IAC (n = 11). METHODS: Retrospective study. An arterial approach via the carotid or femoral artery was utilized to obtain superselective access and administer chemotherapy in the IAC cases. Medical record review was performed, data were recorded, and recorded variables were evaluated statistically. RESULTS: Intraarterial chemotherapy was successfully administered in all cases. There was a significantly greater decrease in longest unidimensional measurement in the IAC group as compared to the IVC group (P = .013). The IAC group was also significantly more likely to have a tumor response as assessed by modified RECIST guidelines (P = .049). Dogs in the IAC group were significantly less likely to develop anemia (P = .001), lethargy (P = .010) and anorexia (P = .024). CONCLUSION AND CLINICAL IMPORTANCE: This study demonstrated the feasibility and efficacy of performing IAC for lower urinary tract neoplasia. Further investigation is necessary as the follow-up time was short and the impact on long-term outcome and survival was not determined.


Subject(s)
Antineoplastic Agents/therapeutic use , Carboplatin/therapeutic use , Dog Diseases/drug therapy , Urologic Neoplasms/veterinary , Administration, Intravenous/veterinary , Animals , Antineoplastic Agents/administration & dosage , Carboplatin/administration & dosage , Carotid Arteries , Dogs , Female , Femoral Artery , Infusions, Intra-Arterial/veterinary , Male , Retrospective Studies , Treatment Outcome , Urologic Neoplasms/drug therapy
4.
Vet Comp Oncol ; 13(1): 70-6, 2015 Mar.
Article in English | MEDLINE | ID: mdl-23451809

ABSTRACT

Completeness of mast cell tumour (MCT) excision is determined by assessment of histologically tumour-free margins (HTFM). The HTFM width necessary to prevent local recurrence (LR), recognized as histologic safety margin (HSM) in human oncology, has not been defined. We hypothesized that HTFM width would correlate with risk for LR and high-grade tumours would require wider HTFM than low-grade tumours. Records of dogs with completely excised MCTs were included. Signalment, two-tier tumour grade, tumour size, HTFM width, recurrence and therapy data was collected. High-grade (n = 39) tumours were more likely to recur than low-grade (n = 51) tumours (35.9% versus 3.9%), P < 0.0001, with no association between HTFM width and LR. Twenty-nine percent of low-grade tumours had HTFM less than 3 mm; none recurred. Narrow (≤3 mm) histologic margins are likely adequate to prevent LR of low-grade tumours. High-grade tumours have significant risk of LR regardless of HTFM width.


Subject(s)
Dog Diseases/surgery , Mastocytoma/veterinary , Neoplasm Grading , Neoplasm Recurrence, Local/veterinary , Animals , Dog Diseases/classification , Dogs , Mastocytoma/classification , Mastocytoma/surgery , Retrospective Studies
5.
Vet Comp Oncol ; 12(4): 266-76, 2014 Dec.
Article in English | MEDLINE | ID: mdl-22998454

ABSTRACT

Febrile neutropenia (FN) is an important sequela in veterinary patients receiving chemotherapy. The purpose of this study was to identify factors associated with prolonged hospital stay and outcome in canine patients developing FN secondary to chemotherapy administration. Medical records of 70 dogs treated for FN at the University of Pennsylvania from 1997 to 2010 were retrospectively evaluated. The mean interval between chemotherapy and hospitalization was 7 days. Two-thirds of treated patients had lymphoma. The majority of patients (70%) received vincristine or doxorubicin prior to the development of FN. Tachycardia at admission, complicating medical issues, G-CSF use and decreasing neutrophil count after admission were associated with prolonged hospital stay. Hypotension and G-CSF use were significantly associated with death in-hospital. Mortality was 8.5%. Identification of factors associated with prolonged hospital stay and mortality in patients with FN may enable the development of risk-adapted treatment guidelines to minimize chemotherapy-associated morbidity and mortality.


Subject(s)
Antineoplastic Agents/adverse effects , Chemotherapy-Induced Febrile Neutropenia/veterinary , Dog Diseases/drug therapy , Length of Stay/statistics & numerical data , Neoplasms/veterinary , Animals , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy-Induced Febrile Neutropenia/complications , Chemotherapy-Induced Febrile Neutropenia/mortality , Comorbidity , Dog Diseases/etiology , Dog Diseases/mortality , Dogs , Female , Hospitals, Animal , Logistic Models , Lymphoma/complications , Lymphoma/drug therapy , Lymphoma/veterinary , Male , Neoplasms/classification , Neoplasms/complications , Neoplasms/drug therapy , Pennsylvania/epidemiology , Retrospective Studies , Risk Factors , Schools, Veterinary , Tachycardia/complications , Treatment Outcome
6.
Vet Comp Oncol ; 12(4): 277-86, 2014 Dec.
Article in English | MEDLINE | ID: mdl-23078083

ABSTRACT

Sterile haemorrhagic cystitis (SHC) is a known risk of cyclophosphamide treatment; however, most canine reports are case series. This case-control study examined risk factors for SHC in dogs with lymphoma receiving oral cyclophosphamide. Twenty-two dogs with SHC and 66 control dogs were identified. On univariate analysis, SHC risk factors included age (P = 0.041), induction protocol (P = 0.021) and cumulative cyclophosphamide dose (P = 0.002). On multivariate analysis, increasing cumulative cyclophosphamide dose was associated with increased risk of SHC and the 'short' induction protocol (protocol 1) was associated with decreased risk. Controlling for age and induction protocol, odds of SHC increased by 2.21 per 750 mg m(-2) increase in cyclophosphamide dose (P = 0.001). SHC from oral cyclophosphamide is a predominately delayed toxicity resulting from high cumulative doses.


Subject(s)
Antineoplastic Agents, Alkylating/adverse effects , Cyclophosphamide/adverse effects , Cystitis/veterinary , Dog Diseases/drug therapy , Dog Diseases/etiology , Hemorrhage/veterinary , Administration, Oral , Animals , Antineoplastic Agents, Alkylating/therapeutic use , Case-Control Studies , Cyclophosphamide/therapeutic use , Cystitis/chemically induced , Dogs , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Hemorrhage/chemically induced , Lymphoma/drug therapy , Lymphoma/veterinary , Male , Multivariate Analysis , Pennsylvania , Risk Factors , Schools, Veterinary
7.
J Vet Intern Med ; 27(4): 935-42, 2013.
Article in English | MEDLINE | ID: mdl-23701181

ABSTRACT

BACKGROUND: Nonmalignant mammary tumors (NMT) are common in intact female dogs. Little is known about the clinical significance of these tumors, and the effect of ovariohysterectomy (OHE) on their development. HYPOTHESIS: Ovarian hormone ablation through OHE decreases the risk of new tumors and thereby improves long-term prognosis for dogs with NMT. ANIMALS: Eighty-four sexually intact bitches with NMT. METHODS: Dogs were allocated to undergo OHE (n = 42) or not (n = 42) at the time of NMT removal in a randomized clinical trial. Tumor diagnosis was confirmed histologically in all subjects. Information about new tumor development was collected via follow-up phone calls and recheck examinations. Separate survival analyses were performed with the endpoints new tumor development and death. Cause of death was classified as related or unrelated to mammary tumor. In addition to OHE status, the influence of age, body weight, breed, tumor size, tumor number, tumor duration, type of surgery, and tumor histology was investigated. RESULTS: New mammary tumor(s) developed in 27 of 42 (64%) intact dogs and 15 of 42 (36%) ovariohysterectomized dogs (hazard ratio 0.47, P = .022). Nine of the 42 dogs (21%) which developed new tumors were euthanized because of mammary tumor. Survival was not significantly different between the 2 treatment groups. In the intact group, nine dogs subsequently developed ovarian-uterine diseases. CONCLUSION: Ovariohysterectomy performed at the time of mammary tumor excision reduced the risk of new tumors by about 50% among dogs with NMT. Survival was not significantly affected. Adjuvant OHE should be considered in adult dogs with mammary tumors.


Subject(s)
Dog Diseases/surgery , Hysterectomy/veterinary , Mammary Neoplasms, Animal/pathology , Ovariectomy/veterinary , Animals , Dogs , Female , Hyperplasia/pathology , Hyperplasia/veterinary , Mammary Glands, Animal/pathology , Multivariate Analysis
8.
Vet Comp Oncol ; 11(4): 272-86, 2013 Dec.
Article in English | MEDLINE | ID: mdl-22296667

ABSTRACT

Indolent lymphoma comprises up to 29% of all canine lymphoma; however, limited information exists regarding the subtypes and biological behaviour. This retrospective study describes the clinical characteristics, histopathological and immunohistochemical features, treatment, outcome and prognostic factors for 75 dogs with indolent lymphoma. WHO histopathological classification and immunohistochemistry (IHC) for CD79a, CD3, Ki67 and P-glycoprotein (P-gp) was performed. The most common histopathological subtype was T-zone, 61.7%, (MST 33.5 months), followed by marginal zone, 25%, (MST 21.2 months), P = 0.542. The addition of IHC to preliminary histopathological classification resulted in a revised diagnosis in 20.4% of cases. The use of systemic treatment did not influence survival, P = 0.065. Dogs treated with chlorambucil and prednisone did not reach a MST, compared with a MST of 21.6 months with CHOP-based chemotherapy, P = 0.057. The overall MST of 4.4 years confirms that this is indeed an indolent disease. However, the effect of systemic treatment must be determined through prospective trials.


Subject(s)
Dog Diseases/pathology , Immunohistochemistry/veterinary , Lymphoma/veterinary , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Animals , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor , CD3 Complex/genetics , CD3 Complex/metabolism , CD79 Antigens/genetics , CD79 Antigens/metabolism , Cohort Studies , Dogs , Female , Gene Expression Regulation, Neoplastic/physiology , Ki-67 Antigen/genetics , Ki-67 Antigen/metabolism , Lymphoma/drug therapy , Lymphoma/pathology , Male , Retrospective Studies , Survival Analysis
9.
J Vet Intern Med ; 27(1): 134-40, 2013.
Article in English | MEDLINE | ID: mdl-23157371

ABSTRACT

BACKGROUND: Current standard chemotherapy protocols for lymphoma in cats carry risks of gastrointestinal toxicity, which can decrease quality of life and complicate response assessment. Protocols with less gastrointestinal toxicity may improve treatment tolerance. HYPOTHESIS/OBJECTIVES: The study purpose was to compare response rate, outcome, and toxicity between cats that received vincristine or vinblastine as part of combination chemotherapy for lymphoma. We hypothesized that vinblastine would have similar efficacy, but less gastrointestinal toxicity, compared with vincristine. ANIMALS: Forty client-owned cats with confirmed diagnosis of lymphoma. METHODS: Cats were randomized to 1 of 2 treatment arms and received weekly COP-based chemotherapy for 6 months or until disease progression. Response rate, progression-free survival (PFS), lymphoma-specific survival (LSS), and incidence and severity of gastrointestinal and hematologic toxicity were compared between arms. Arm cross-over occurred if specific gastrointestinal toxicity criteria were noted. RESULTS: Cats in both arms had similar response rates, PFS, and LSS (48 versus 64 days, P = .87; 139 versus 136 days, P = .96). Cats that received vincristine were significantly more likely to switch arms based on gastrointestinal toxicity than cats that received vinblastine (44.4 versus 10.5%, P = .02). Lower baseline weight was significantly negatively associated with PFS and LSS (P = .01, P = .003, respectively). Baseline anemia was significantly negatively associated with LSS (P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that vinblastine is a reasonable alternative to vincristine in the treatment of some cats with lymphoma. Baseline body weight remains a significant prognostic factor for cats with lymphoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Cat Diseases/drug therapy , Lymphoma/veterinary , Vinblastine/therapeutic use , Vincristine/therapeutic use , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Cats , Female , Lymphoma/drug therapy , Male
10.
Vet Pathol ; 48(1): 85-97, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21147765

ABSTRACT

Mammary neoplasms are the most common neoplasm in female dogs. This article describes the embryologic development, normal anatomy, and histology of the canine mammary gland from the onset of first estrous and the changes that occur in the mammary gland during the estrus cycle. The clinical features of canine mammary gland tumors and their relation to prognosis are discussed, including age, hormones, breed, diet, and obesity. Additional clinical prognostic factors including clinical presentation, tumor size, and lymph node status at the time of presentation are discussed in relation to diagnosis and tumor staging. Immunohistochemical evaluation of the cell differentiation markers of the normal and neoplastic canine mammary gland is described and compared with similar studies in humans; the ways these markers may be used to assist with the prognosis of canine mammary neoplasms are discussed.


Subject(s)
Biomarkers, Tumor/metabolism , Dog Diseases/pathology , Mammary Neoplasms, Animal/pathology , Animals , Dogs , Female , Lymphatic System , Mammary Glands, Animal/anatomy & histology , Mammary Glands, Animal/physiology , Prognosis , Risk Factors
11.
Vet Pathol ; 48(1): 7-18, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20664014

ABSTRACT

There is an increasing need for more accurate prognostic and predictive markers in veterinary oncology because of an increasing number of treatment options, the increased financial costs associated with treatment, and the emotional stress experienced by owners in association with the disease and its treatment. Numerous studies have evaluated potential prognostic and predictive markers for veterinary neoplastic diseases, but there are no established guidelines or standards for the conduct and reporting of prognostic studies in veterinary medicine. This lack of standardization has made the evaluation and comparison of studies difficult. Most important, translating these results to clinical applications is problematic. To address this issue, the American College of Veterinary Pathologists' Oncology Committee organized an initiative to establish guidelines for the conduct and reporting of prognostic studies in veterinary oncology. The goal of this initiative is to increase the quality and standardization of veterinary prognostic studies to facilitate independent evaluation, validation, comparison, and implementation of study results. This article represents a consensus statement on the conduct and reporting of prognostic studies in veterinary oncology from veterinary pathologists and oncologists from around the world. These guidelines should be considered a recommendation based on the current state of knowledge in the field, and they will need to be continually reevaluated and revised as the field of veterinary oncology continues to progress. As mentioned, these guidelines were developed through an initiative of the American College of Veterinary Pathologists' Oncology Committee, and they have been reviewed and endorsed by the World Small Animal Veterinary Association.


Subject(s)
Medical Oncology/standards , Neoplasms/veterinary , Practice Guidelines as Topic , Veterinary Medicine/standards , Animals , Disease Progression , Neoplasms/pathology , Prognosis
12.
Vet Comp Oncol ; 8(3): 221-33, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20691029

ABSTRACT

Eighteen dogs with measurable subcutaneous haemangiosarcoma (SQHSA) were treated with doxorubicin-based chemotherapy. Response assessment was evaluated and compared using World Health Organization (WHO), Response Evaluation Criteria in Solid Tumours (RECIST) and tumour volume criteria. The overall response rate for all dogs was 38.8% using WHO criteria, 38.8% using RECIST criteria and 44% using tumour volume criteria. One dog had a complete response. The median response duration for all dogs was 53 days (range 13-190 days). Four dogs had complete surgical excision after neoadjuvant chemotherapy. The median progression-free interval for dogs with complete surgical excision after neoadjuvant chemotherapy was significantly longer than those not having surgical excision (207 days versus 83 days, respectively) (P = 0.003). No significant difference in metastasis-free interval or survival time was found between the groups. Doxorubicin-based chemotherapy appears to be effective for non-resectable canine SQHSA, although the response duration is relatively short.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Dog Diseases/drug therapy , Doxorubicin/therapeutic use , Hemangiosarcoma/veterinary , Soft Tissue Neoplasms/veterinary , Animals , Chemotherapy, Adjuvant/veterinary , Dog Diseases/pathology , Dog Diseases/surgery , Dogs , Female , Hemangiosarcoma/drug therapy , Hemangiosarcoma/secondary , Hemangiosarcoma/surgery , Male , Neoplasm Metastasis , Soft Tissue Neoplasms/drug therapy , Soft Tissue Neoplasms/pathology , Soft Tissue Neoplasms/surgery , Survival Analysis , Treatment Outcome
13.
Vet Comp Oncol ; 8(2): 122-6, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20579325

ABSTRACT

The purpose of this study was to evaluate the variability of cystosonographic bladder tumor measurements with both operator and bladder volume changes. Ten dogs with bladder tumors were included. In each dog, three operators determined tumor dimensions for three different bladder volumes. Intraclass correlation coefficient was used to assess operator reliability. Response Evaluation Criteria in Solid Tumors (RECIST) and greater than or equal to 50% differences in tumor measurements were used as guidelines. Poor to fair correlations between operators were found for the different tumor dimensions (r(I) = 0.4 - 0.7). The percent differences in tumor dimensions with operator and bladder volume changes were significant enough to misclassify the tumors into the categories of partial response (PR) or progressive disease (PD). These results suggest that cystosonographic measurements of bladder tumors are affected by both changes in operator and bladder volume, and the discrepancies are significant enough to change response classification.


Subject(s)
Dog Diseases/diagnostic imaging , Urinary Bladder Neoplasms/veterinary , Animals , Dog Diseases/pathology , Dogs , Observer Variation , Organ Size , Pathology, Veterinary/standards , Ultrasonography , Urinary Bladder/diagnostic imaging , Urinary Bladder/pathology , Urinary Bladder Neoplasms/diagnostic imaging , Urinary Bladder Neoplasms/pathology
14.
Vet Comp Oncol ; 7(3): 162-72, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19691645

ABSTRACT

This study describes the clinical and histopathological findings in dogs with mammary gland tumours, and compares the histopathological and clinical evidence consistent with progression from benign to malignant to human breast cancer epidemiology. Clinical and histopathological data on 90 female dogs with 236 tumours was included. Dogs with malignant tumours were significantly older than dogs with benign tumours (9.5 versus 8.5 years), P = 0.009. Malignant tumours were significantly larger than benign tumours (4.7 versus 2.1 cm), P = 0.0002. Sixty-six percent had more than one tumour, and evidence of histological progression was noted with increasing tumour size. Dogs with malignant tumours were significantly more likely to develop new primary tumours than dogs with benign tumours, P = 0.015. These findings suggest that canine mammary tumours progress from benign to malignant; malignant tumours may be the end stage of a histological continuum with clinical and histopathological similarities to human breast carcinogenesis.


Subject(s)
Dog Diseases/pathology , Mammary Neoplasms, Animal/pathology , Mixed Tumor, Malignant/veterinary , Neoplasms/veterinary , Adenocarcinoma/veterinary , Adenoma/veterinary , Animals , Carcinoma/veterinary , Dogs , Female , Mixed Tumor, Malignant/pathology , Neoplasms/pathology , Neoplasms, Complex and Mixed/pathology , Neoplasms, Complex and Mixed/veterinary , Neoplasms, Glandular and Epithelial/veterinary , Retrospective Studies
15.
Vet Comp Oncol ; 7(2): 130-8, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19453367

ABSTRACT

The purpose of this retrospective cohort study is to describe the association of cytological assessment of lymph node metastasis with survival and tumour grade in dogs with mast cell tumours. Regional lymph node aspirates of 152 dogs diagnosed with a mast cell tumour were reviewed and classified according to specific cytological criteria for staging. 97 dogs (63.8%) had stage I tumours, and 55 (36.2%) had stage II tumours. Stage II dogs had a significantly shorter survival time than dogs with stage I disease (0.8 and 6.2 years, respectively; P < 0.0001). Dogs with grade III mast cell tumours were more likely to have stage II disease (P = 0.004). These results suggest that cytological evaluation of lymph nodes in dogs with mast cell tumours provides useful and valuable clinical information, and the results correlate with tumour grade and outcome thus providing a practical and non-invasive method for staging.


Subject(s)
Dog Diseases/mortality , Dog Diseases/pathology , Lymph Nodes/cytology , Mast-Cell Sarcoma/veterinary , Neoplasm Staging/veterinary , Animals , Cohort Studies , Dogs , Female , Lymph Nodes/pathology , Lymphatic Metastasis/pathology , Male , Mast-Cell Sarcoma/mortality , Mast-Cell Sarcoma/pathology , Retrospective Studies , Sentinel Lymph Node Biopsy/veterinary , Survival Analysis
16.
J Vet Intern Med ; 23(1): 123-9, 2009.
Article in English | MEDLINE | ID: mdl-19175730

ABSTRACT

BACKGROUND: Feline mammary carcinomas (FMC) are locally invasive and highly metastatic tumors. Because of the high metastatic potential, patients often are treated with adjuvant doxorubicin-based chemotherapy, but little data exist to evaluate the effect of this strategy. HYPOTHESIS: Adjuvant doxorubicin-based chemotherapy improves outcome for FMC compared with surgery alone. ANIMALS: Cats with naturally occurring, biopsy-confirmed FMC treated with either surgery alone (Sx) or with surgery plus adjuvant doxorubicin-based chemotherapy (Sx + Chemo). METHODS: Retrospective cohort study. Clinical data were collected and compared to identify differences between groups. Outcome results were determined and compared. Prognostic factors for disease-free survival (DFS) and overall survival were evaluated. RESULTS: Seventy-three cats were evaluated, of which 37 were in the Sx group and 36 in the Sx + Chemo group. No differences in clinical data were found between Sx and Sx + Chemo groups. Median DFS times for the Sx and Sx + Chemo groups were 372 and 676 days, respectively (P= .15) and median survival times (ST) were 1,406 and 848 days, respectively (P= .78). For cats that underwent a unilateral radical mastectomy, ST was significantly longer for the Sx + Chemo compared with the Sx group (1,998 versus 414 days, respectively; P= .03). CONCLUSIONS AND CLINICAL IMPORTANCE: This study did not find a benefit to adjuvant doxorubicin-based chemotherapy in cats with FMC. Additional studies are required to determine whether patient subgroups with negative prognostic factors may benefit from adjuvant chemotherapy.


Subject(s)
Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Cat Diseases/drug therapy , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Mammary Neoplasms, Animal/drug therapy , Animals , Cat Diseases/surgery , Cats , Chemotherapy, Adjuvant , Cohort Studies , Cyclophosphamide/administration & dosage , Cyclophosphamide/therapeutic use , Female , Male , Mammary Neoplasms, Animal/surgery , Retrospective Studies
17.
Gene Ther ; 15(13): 955-65, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18337841

ABSTRACT

Cell-based vaccination strategies to induce functional tumor-specific T cells in cancer patients have focused on using autologous dendritic cells. An alternative approach is to use RNA-loaded CD40 activated B cells (CD40-B) that are highly efficient antigen-presenting cells capable of priming naive T cells, boosting memory T-cell responses and breaking tolerance to tumor antigens. The use of tumor RNA as the antigenic payload allows for gene transfer without viruses or vectors and permits major histocompatibility complex (MHC)-independent, multiple-antigen targeting. Here, we use CD40L transfected K562 cells to generate functional CD40-B cells from the peripheral blood of humans and dogs. Testing of RNA-loaded CD40-B cells in dogs allows not only for its development in veterinary medicine but also for determination of its safety and efficacy in a large animal model of spontaneous cancer prior to initiation of human clinical trials. We found that CD40-B cells from healthy humans, healthy dogs and tumor-bearing dogs express increased levels of immune molecules such as MHC and CCR7. Moreover, RNA-loaded CD40-B cells induce functional, antigen-specific T cells from healthy dogs and dogs with lymphoma. These findings pave the way for immunotherapy trials using tumor RNA-loaded CD40-B cells to stimulate antitumor immunity in a large animal model of spontaneous neoplasia.


Subject(s)
Dog Diseases/therapy , Genetic Therapy/methods , Immunotherapy, Adoptive/methods , Lymphoma/therapy , Lymphoma/veterinary , RNA, Neoplasm/genetics , Animals , Antigen-Presenting Cells/immunology , Base Sequence , CD40 Antigens/immunology , Cell Line, Tumor , Cells, Cultured , Dog Diseases/immunology , Dogs , Humans , Immunophenotyping , Lymphocyte Activation , Lymphoma/immunology , Molecular Sequence Data , Receptors, CCR7/genetics , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocytes/immunology , Transfection
18.
Vet Comp Oncol ; 6(2): 102-10, 2008 Jun.
Article in English | MEDLINE | ID: mdl-19178669

ABSTRACT

Feline large granular lymphocyte (LGL) lymphoma is an uncommon, morphologically distinct variant of feline lymphoma. Limited information exists in the literature regarding pathological and immunohistochemical descriptions, clinical findings, treatment and survival times. The purpose of this study was to describe clinical features, treatment and outcome in feline LGL lymphoma. Medical records of 45 cats with LGL lymphoma were retrospectively evaluated. Decreased appetite/anorexia, weight loss, lethargy and vomiting were the most commonly reported clinical signs. All cats tested for feline leukaemia virus and feline immunodeficiency virus infection were negative. The mesenteric lymph nodes and small intestine were the most commonly affected organs. One complete response and six partial responses were noted in the 23 cats that received chemotherapy as their initial treatment. Median survival time for cats that were treated was 57 days. Based on these results, feline LGL lymphoma appears to be minimally responsive to chemotherapy and is associated with a grave prognosis.


Subject(s)
Antineoplastic Agents/therapeutic use , Cat Diseases/pathology , Lymphoma/veterinary , Precursor Cell Lymphoblastic Leukemia-Lymphoma/veterinary , Animals , Cat Diseases/drug therapy , Cats , Female , Immunohistochemistry/veterinary , Lymphoma/drug therapy , Lymphoma/pathology , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prognosis , Retrospective Studies , Survival Analysis , Treatment Outcome
19.
Vet Comp Oncol ; 6(2): 120-5, 2008 Jun.
Article in English | MEDLINE | ID: mdl-19178671

ABSTRACT

Small to intermediate cell alimentary lymphoma was diagnosed in a cat after abdominal exploratory surgery with no prior history of pulmonary disease. Initial response to several chemotherapy regimens was poor, but a long-term remission was achieved with CCNU (lomustine) and corticosteroid therapy. After receiving a total cumulative CCNU dose of 552 mg m(-2) over 12 months, an acute episode of respiratory distress occurred and the cat died. Necropsy identified severe diffuse pulmonary fibrosis and no signs of lymphoma. This is the first report of pulmonary fibrosis following high cumulative dose nitrosourea chemotherapy in a cat.


Subject(s)
Antineoplastic Agents, Alkylating/adverse effects , Cat Diseases/chemically induced , Lomustine/adverse effects , Pulmonary Fibrosis/veterinary , Adrenal Cortex Hormones/adverse effects , Adrenal Cortex Hormones/therapeutic use , Animals , Antineoplastic Agents, Alkylating/therapeutic use , Cat Diseases/mortality , Cats , Fatal Outcome , Lomustine/therapeutic use , Lymphoma/drug therapy , Lymphoma/veterinary , Male , Pulmonary Fibrosis/chemically induced
20.
Vet Comp Oncol ; 5(2): 90-8, 2007 Jun.
Article in English | MEDLINE | ID: mdl-19754792

ABSTRACT

The purpose of this retrospective study was to compare Rottweilers diagnosed with osteosarcoma (OSA) with other breeds to determine whether Rottweilers experienced a more aggressive form of the disease. Two hundred and fifty-eight dogs were evaluated (102 clinical and 156 necropsy cases). In the necropsy population, Rottweilers had a younger mean age at death (7.3 versus 9 years, P = 0.006). There were no significant differences between Rottweilers and other breeds in age at diagnosis, median disease-free interval or survival time. However, Rottweilers were more likely to have metastasis to the brain (7 versus 0%, P = 0.03). These results suggest that OSA in Rottweilers may have a different biological behaviour, but this study did not confirm that these differences were associated with a worse outcome.

SELECTION OF CITATIONS
SEARCH DETAIL
...